The Lunit SCOPE PD-L1 does AI-based quantification of tissue samples using a scoring system. Integrating it with the Guardant test will enhance biomarker assessment for NSCLC patients, the company claimed in a press statement. The AI has helped lift the test's detection of PD-L1 by over 20% compared to manual pathologist interpretation.

Lunit is an AI software company devoted to developing advanced medical image analytics and data-driven imaging biomarkers via cutting-edge deep learning technology. AutoML team develops a cloud-based AutoML platform and AutoML algorithms that run on the platform. Our team already has built a cloud-based hyperparameter tuning platform and achieved significant performance improvements in the real-world products with the power of AutoML. Recently, we are focusing on improving the AutoML algorithm to further boost the performance of various AI models in Lunit. We are looking for a research scientist with a strong motivation to achieve meaningful improvements in real-world scenarios.

Lunit, a leading medical AI provider serving more than 1,000 medical sites globally, announced that the company has joined the World Economic Forum's Global Innovators Community, a group of the world's most promising start-ups and scale-ups that are at the forefront of ethical technological and business model innovation. The World Economic Forum provides the Global Innovators Community with a platform to engage with public- and private-sector leaders and to contribute new solutions to overcome current crises and build future resiliency. As part of the Global Innovators Community, Lunit will engage with the Forum's Platforms to help define the global agenda on key issues. "We're pleased to welcome Lunit to the Global Innovators Community and we're looking forward to leveraging their insights to inform our content work on the Forum's Platform for Shaping the Future of Health and Healthcare," said Verena Kuhn, Global Innovators Community Head, World Economic Forum. "Lunit is honored to accept the World Economic Forum's recognition as a global innovator," said Brandon Suh.

First Korean healthcare company to obtain "AA-AA" ratings in technology assessment for its FDA-cleared and CE-marked solutions Lunit intends to list its common stock on the KOSDAQ market under the ticker code "A32813". NH Investment & Securities will act as book-running manager, backing Lunit's debut. A total of 1,124,300 shares will be offered in the price range of KRW 44,000 to 49,000 ($34-38). The exact price will be determined after recording the demand of institutional investors on July 7-8, while retail buyers can take part in the public subscription during July 12-13. Based on the low end of the targeted range, Lunit expects to raise about KRW 54 billion ($42 million).

Lunit, a leading medical AI software company devoted to providing AI-powered total cancer care, will be returning to the 105th Radiological Society of North America (RSNA) this year with the latest, up-to-date AI solutions for chest and breast radiology. The state-of-the-art software--Lunit INSIGHT CXR 3 and Lunit INSIGHT MMG--will be available for demonstration at the Lunit booth located on AI Showcase floor, #10732. During RSNA 2019, Lunit will present key clinical study results conducted to validate the specific clinical utility of its products, along with other abstracts that study AI-driven mammography & DBT, and AI-based detection of chest abnormalities such as pneumothorax and tuberculosis. Lunit is one of the few companies in the industry that highlights evidence-based studies and publications. Lunit INSIGHT CXR and Lunit INSIGHT MMG, Lunit's most mature products tested on more than 3 million images from over 80 countries combined, will also be presented for demo.

Lunit is a medical AI company devoted to developing advanced medical image analytics and novel imaging biomarkers with its cutting-edge deep learning technology. The company has been internationally acknowledged for its advanced, state-of-the-art technology and application in analyzing medical images. Lunit specializes in developing medical AI software products that can foster accurate and cost-efficient diagnosis and treatment. By providing an accurate quantitative assessment of disease, products are designed to significantly reduce unnecessary tests, treatment, especially expensive invasive tests, such as biopsies. Currently, the company has released two products that provide AI analysis for chest X-rays and mammograms. The accuracy level of their diagnostic products currently ranges from 97% to 99%, depending on the area of diagnosis.

Lunit Inc., a member company of the K-ICT Born2Global Centre, has developed a deep learning-based technology for analyzing medical images that dramatically lowers the rate of misdiagnosis. Currently, the AI technology is being subjected to a sophistication process in cooperation with major medical institutions in Korea, including Seoul National University Hospital, Severance Hospital of Yonsei University Health System, Samsung Medical Center, and Asan Medical Center. Anthony Paek, the CEO of Lunit, explained, "The data-driven imaging biomarker (DIB) technology that Lunit proposed for the first time ever in 2015 is an AI system that has learned abnormal and clinically significant image patterns from big data." He went on to add, "Currently, DIB technology has achieved an accuracy level comparable to that of human experts. In the future, however, we will have new DIB technologies capable of outperforming humans."

Nvidia is on a quest to find the best "social impact" artificial intelligence startups as part of a program called Nvidia Inception, which is screening more than 600 entrants to cull the best AI startups in three big categories. We wrote about the first four candidates for the hottest emerging startup on Friday and the five most-disruptive startups on Sunday morning. And now we're focusing on the next five candidates in a category dubbed the "potential for social impact" startups. They all happen to be in the medical space. Jen-Hsun Huang, CEO of Nvidia, hosted a Shark Tank-style event last week to narrow down the competition. Huang and a panel of judges listened to pitches from 14 AI startups across three categories.